EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1–CXCR2 induced NETs

Gan Xiong, Zhi Chen, Qianwen Liu, Fang Peng, Caihua Zhang, Maosheng Cheng, Rongsong Ling, Shuang Chen, Yu Liang, Demeng Chen iD, Qimin Zhou iD

Journal for ImmunoTherapy of Cancer · 2024-05 · 12 (5) · e008662

DOI: 10.1136/jitc-2023-008662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 09.05.2024. Verfasst von Gan Xiong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Medicine, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: B7 Antigens, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Extracellular Traps. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Shanghai Pujiang Program, Postdoctoral Research Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CD276 (B7-H3), a pivotal immune checkpoint, facilitates tumorigenicity, invasiveness, and metastasis by escaping immune surveillance in a variety of tumors; however, the underlying mechanisms facilitating immune escape in esophageal squamous cell carcinoma (ESCC) remain enigmatic.

Methods

We investigated the expression of CD276 in ESCC tissues from patients by using immunohistochemistry (IHC) assays. In vivo, we established a 4-nitroquinoline 1-oxide (4NQO)-induced CD276 knockout (CD276 wKO ) and K14cre; CD276 conditional knockout (CD276 cKO ) mouse model of ESCC to study the functional role of CD276 in ESCC. Furthermore, we used the 4NQO-induced mouse model to evaluate the effects of anti-CXCL1 antibodies, anti-Ly6G antibodies, anti-NK1.1 antibodies, and GSK484 inhibitors on tumor growth. Moreover, IHC, flow cytometry, and immunofluorescence techniques were employed to measure immune cell proportions in ESCC. In addition, we conducted single-cell RNA sequencing analysis to examine the alterations in tumor microenvironment following CD276 depletion.

Results

In this study, we elucidate that CD276 is markedly upregulated in ESCC, correlating with poor prognosis. In vivo, our results indicate that depletion of CD276 inhibits tumorigenesis and progression of ESCC. Furthermore, conditional knockout of CD276 in epithelial cells engenders a significant downregulation of CXCL1, consequently reducing the formation of neutrophil extracellular trap networks (NETs) via the CXCL1–CXCR2 signaling axis, while simultaneously augmenting natural killer (NK) cells. In addition, overexpression of CD276 promotes tumorigenesis via increasing NETs’ formation and reducing NK cells in vivo.

Conclusions

This study successfully elucidates the functional role of CD276 in ESCC. Our comprehensive analysis uncovers the significant role of CD276 in modulating immune surveillance mechanisms in ESCC, thereby suggesting that targeting CD276 might serve as a potential therapeutic approach for ESCC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7 AntigensEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaExtracellular TrapsAnimalsFemaleHumansMaleMiceChemokine CXCL1Mice, KnockoutReceptors, Interleukin-8BTumor EscapeTumor Microenvironment

Stichwörter der Autor:innen

Esophageal CancerImmune Checkpoint InhibitorNatural killer - NK

Substanzen

B7 AntigensCD276 protein, humanChemokine CXCL1CXCR2 protein, humanReceptors, Interleukin-8B

Autor:innen und Institutionen

  • Center for Translational Medicine, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China.
  • Department of Thoracic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
  • Department of Radiation Oncology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China.
  • Institute for Advanced Study, Shenzhen University, Shenzhen, Guangdong, China.
  • Center for Translational Medicine, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China qimin.zhou@sjtu.edu.cn chendm29@mail.sysu.edu.cn.
  • Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China qimin.zhou@sjtu.edu.cn chendm29@mail.sysu.edu.cn.

ORCID-Profile: Demeng Chen, Qimin Zhou

Förderung

  • Guangdong Basic and Applied Basic Research Foundation
  • Shanghai Pujiang Program
  • Postdoctoral Research Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Xiong, G., Chen, Z., Liu, Q., Peng, F., Zhang, C., Cheng, M., Ling, R., Chen, S., Liang, Y., Chen, D., & Zhou, Q. (2024). CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1–CXCR2 induced NETs. Journal for ImmunoTherapy of Cancer, 12(5), e008662. https://doi.org/10.1136/jitc-2023-008662

Vancouver

Xiong G, Chen Z, Liu Q, Peng F, Zhang C, Cheng M, et al. CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1–CXCR2 induced NETs. Journal for ImmunoTherapy of Cancer. 2024;12(5):e008662. doi:10.1136/jitc-2023-008662

BibTeX
@article{Xiong2024,
  author = {Xiong, Gan and Chen, Zhi and Liu, Qianwen and Peng, Fang and Zhang, Caihua and Cheng, Maosheng and Ling, Rongsong and Chen, Shuang and Liang, Yu and Chen, Demeng and Zhou, Qimin},
  title = {CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1–CXCR2 induced NETs},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {5},
  pages = {e008662},
  doi = {10.1136/jitc-2023-008662}
}
Kostenlos starten →